摘要
目的探讨碘[131Ⅰ]美妥昔单抗注射液(利卡汀)联合经导管肝动脉化疗栓塞术(TACE)治疗原发性肝癌的疗效。方法选择62例原发性肝癌术后肝内转移患者。将患者随机分成两组,碘[131Ⅰ]美妥昔单抗注射液联合TACE为治疗组(31例),对照组(31例)仅接受TACE治疗,比较两组临床疗效。结果碘[131Ⅰ]美妥昔单抗注射液联合TACE治疗原发性肝癌的实体瘤疗效、生活质量和生存期临床疗效均优于对照组(P<0.05)。结论碘[131Ⅰ]美妥昔单抗注射液可提高TACE治疗原发性肝癌的疗效。
【Objective】 To investigate the effect of iodine[131Ⅰ] metuximab injection combined with TACE on primary liver cancer.【Method】 62 cases with primary liver cancer were divided into two groups randomly.31 cases of them accepted iodine[131Ⅰ] metuximab injection and TACE,the other 31 cases only accept TACE as control.Effect of iodine[131Ⅰ] metuximab injection combined with TACE was evaluated.【Result】 [131Ⅰ] metuximab injection group has better effect than control group in all aspects.【Conclusion】 [131Ⅰ] metuximab injection can improve the effect of TACE on primary liver cancer.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2011年第10期1206-1208,共3页
China Journal of Modern Medicine
关键词
肝癌
美妥昔单抗
联合治疗
经导管肝动脉化疗栓塞术
liver cancer
metuximab
combined treatment
transcatheter arterial chemoembolization
